Kewaunee Scientific (KEQU) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kewaunee Scientific (KEQU) has outperformed Sera Prognostics (SERA) over the past year, losing 22.8% versus a loss of 35.9%. Over five years, KEQU leads with a +156.2% price change compared with -81.4% for SERA. Kewaunee Scientific is the larger company by market cap ($97.9 million vs $82.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KEQU | SERA |
|---|---|---|
| Share price | $33.82 | $2.10 |
| Market cap | $97.92M | $82.80M |
| 1-day change | 0.00% | +3.91% |
| YTD return | -9.60% | -31.53% |
| 1-year return | -22.84% | -35.87% |
| 5-year return | +156.21% | -81.38% |
| P/E ratio (TTM) | 12.25 | — |
| Forward P/E | 15.66 | — |
| EPS (TTM) | $2.76 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.57 | $3.95 |
| 52-week low | $32.00 | $1.56 |
| Distance from 52-week high | -27.38% | -46.86% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +162.03% |
| Average volume | 4.22K | 27.84K |
| Shares outstanding | 2.90M | 38.48M |
| Employees | 1,231 | 71 |
| Sector | Industrials | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KEQU has outperformed SERA by 13.0 percentage points over the past year.
- The two companies sit in different sectors: Kewaunee Scientific in Industrials and Sera Prognostics in Health Care.
About Kewaunee Scientific
KEQU stock →Kewaunee Scientific Corporation, together with its subsidiaries, designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products in the United States and internationally. It operates through two segments, Lab Products Group (LPG) and International.
Industrials · Medical Specialities · 1,231 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
KEQU vs SERA FAQ
Which is bigger, Kewaunee Scientific or Sera Prognostics?
Kewaunee Scientific (KEQU) is larger, with a market capitalization of $97.92M compared with $82.80M for Sera Prognostics (SERA).
Which stock has performed better over the past year, KEQU or SERA?
KEQU returned -22.84% over the past 12 months, compared with -35.87% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Kewaunee Scientific and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Industrials sector.